Anti-Müllerian hormone - Revision history

Andrea: Reviewed and expanded entry, added graph

2023-03-26T12:09:14Z

Reviewed and expanded entry, added graph

Dmitry Dzhagarov at 12:16, 16 March 2023

2023-03-16T12:16:56Z

← Older revision		Revision as of 12:16, 16 March 2023
Line 4:		Line 4:

	<ref>Durlinger, A., Visser, J., & Themmen, A. (2002). Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction. PMID: 12416998 DOI: 10.1530/rep.0.1240601</ref>		<ref>Durlinger, A., Visser, J., & Themmen, A. (2002). Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction. PMID: 12416998 DOI: 10.1530/rep.0.1240601</ref>
	The measurement of circulating anti-Müllerian hormone (AMH) has been applied to a wide array of clinical applications, mainly based on its ability to reflect the number of antral and pre-antral follicles present in the ovaries. AMH has been suggested to predict the ovarian response to hyperstimulation of the ovaries for IVF and the timing of menopause, and to indicate iatrogenic damage to the ovarian follicle reserve. It has also been proposed as a surrogate for antral follicle count (AFC) in the diagnosis of polycystic ovary syndrome (PCOS).		The measurement of circulating anti-Müllerian hormone (AMH) has been applied to a wide array of clinical applications, mainly based on its ability to reflect the number of antral and pre-antral follicles present in the ovaries. AMH has been suggested to predict the ovarian response to hyperstimulation of the ovaries for IVF and the timing of menopause, and to indicate iatrogenic damage to the ovarian follicle reserve. It has also been proposed as a surrogate for antral follicle count (AFC) in the diagnosis of polycystic ovary syndrome (PCOS).<ref>Di Clemente, N., Racine, C., Pierre, A., & Taieb, J. (2021). Anti-Müllerian hormone in female reproduction. Endocrine reviews, 42(6), 753-782. PMID: 33851994 DOI: 10.1210/endrev/bnab012</ref>

			Anti-Mullerian hormone (AMH) is vital in the pathophysiological process of polycystic ovary syndrome (PCOS). AMH levels correlated positively with Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) levels and negatively with body mass indices (BMI).<ref>Zhao, H., Zhou, D., Liu, C., & Zhang, L. (2023). The Relationship Between Insulin Resistance and Obesity and Serum Anti-Mullerian Hormone Level in Chinese Women with Polycystic Ovary Syndrome: A Retrospective, Single-Center Cohort Study. International Journal of Women's Health, 151-166. PMID: 36778752 PMCID: PMC9911904 DOI: 10.2147/IJWH.S393594</ref>

	<ref>Nelson, S. M., Davis, S. R., Kalantaridou, S., Lumsden, M. A., Panay, N., & Anderson, R. A. (2023). Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. Human Reproduction Update.</ref>		<ref>Nelson, S. M., Davis, S. R., Kalantaridou, S., Lumsden, M. A., Panay, N., & Anderson, R. A. (2023). Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. Human Reproduction Update.</ref>
	<ref>Holt, R., Yahyavi, S. K., Kooij, I., Andreassen, C. H., Andersson, A. M., Juul, A., ... & Blomberg Jensen, M. (2023). Low serum anti-Müllerian hormone is associated with semen quality in infertile men and not influenced by vitamin D supplementation. BMC medicine, 21(1), 79.</ref>		<ref>Holt, R., Yahyavi, S. K., Kooij, I., Andreassen, C. H., Andersson, A. M., Juul, A., ... & Blomberg Jensen, M. (2023). Low serum anti-Müllerian hormone is associated with semen quality in infertile men and not influenced by vitamin D supplementation. BMC medicine, 21(1), 79.</ref>
	<ref>Sivanandy, M. S., & Ha, S. K. (2023). The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome. Diagnostics, 13(5), 907.</ref>		<ref>Sivanandy, M. S., & Ha, S. K. (2023). The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome. Diagnostics, 13(5), 907.</ref>

			<ref>Edelsztein, N. Y., Valeri, C., Lovaisa, M. M., Schteingart, H. F., & Rey, R. A. (2022). AMH regulation by steroids in the mammalian testis: Underlying mechanisms and clinical implications. Frontiers in Endocrinology, 13. PMID: 35712256 PMCID: PMC9195137 DOI: 10.3389/fendo.2022.906381</ref>

	(AMH) is an ideal biomarker for the assessment of ovarian reserve. However, the ovarian reserve of premature ovarian insufficiency (POI) patients declines over time even under hormone therapy-treatment.<ref>Kuang, X., Wei, L., Huang, Y., Ji, M., Tang, Y., Wei, B., ... & Xu, H. (2023). Development of a digital anti-Müllerian hormone immunoassay: ultrasensitive, accurate and practical strategy for reduced ovarian reserve monitoring and assessment. Talanta, 253, 123970. PMID: 36206626 DOI: 10.1016/j.talanta.2022.123970</ref>		(AMH) is an ideal biomarker for the assessment of ovarian reserve. However, the ovarian reserve of premature ovarian insufficiency (POI) patients declines over time even under hormone therapy-treatment.<ref>Kuang, X., Wei, L., Huang, Y., Ji, M., Tang, Y., Wei, B., ... & Xu, H. (2023). Development of a digital anti-Müllerian hormone immunoassay: ultrasensitive, accurate and practical strategy for reduced ovarian reserve monitoring and assessment. Talanta, 253, 123970. PMID: 36206626 DOI: 10.1016/j.talanta.2022.123970</ref>

Dmitry Dzhagarov at 11:59, 16 March 2023

2023-03-16T11:59:02Z

@@ Line 1: / Line 1: @@
 '''Anti-Müllerian hormone'''(AMH), also known as Müllerian inhibiting substance, is a glycoprotein hormone that belongs to the transforming growth factor beta (TGF-β) superfamily of growth and differentiation factors secreted by immature Sertoli cells (after castration, AMH is no longer detected in serum) and by granulosa cells of growing ovarian follicles. In males, it induces the regression of fetal Müllerian ducts and represses androgen synthesis through receptors located on the Leydig cell membrane. In female, AMH inhibits primary follicle recruitment and sensitivity to [[Follicle-stimulating hormone (FSH)]].
 AMH is synthesized as a homodimeric precursor consisting of two identical polypeptide chains, with a large N-terminal pro-region of 110-kDa and a small C-terminal mature domain of 25-kDa. AMH is subjected to post-translational proteolytic processing; the resulting N-terminal and C-terminal dimers remain associated in a non-covalent complex that is biologically active.<ref>Rajpert-De Meyts, E., Jørgensen, N., Græm, N., Müller, J., Cate, R. L., & Skakkebæk, N. E. (1999). Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. The Journal of Clinical Endocrinology & Metabolism, 84(10), 3836-3844. PMID: 10523039 DOI: 10.1210/jcem.84.10.6047</ref>
@@ Line 10: / Line 11: @@
 (AMH) is an ideal biomarker for the assessment of ovarian reserve. However, the ovarian reserve of premature ovarian insufficiency (POI) patients declines over time even under hormone therapy-treatment.<ref>Kuang, X., Wei, L., Huang, Y., Ji, M., Tang, Y., Wei, B., ... & Xu, H. (2023). Development of a digital anti-Müllerian hormone immunoassay: ultrasensitive, accurate and practical strategy for reduced ovarian reserve monitoring and assessment. Talanta, 253, 123970. PMID: 36206626 DOI: 10.1016/j.talanta.2022.123970</ref>

Dmitry Dzhagarov: Created page with "'''Anti-Müllerian hormone'''(AMH), also known as Müllerian inhibiting substance, is a glycoprotein hormone that belongs to the transforming growth factor beta (TGF-β) superfamily of growth and differentiation factors secreted by immature Sertoli cells (after castration, AMH is no longer detected in serum) and by granulosa cells of growing ovarian follicles. In males, it induces the regression of fetal Müllerian ducts and represses androgen synthesis through receptors..."

2023-03-16T11:55:35Z

Created page with "'''Anti-Müllerian hormone'''(AMH), also known as Müllerian inhibiting substance, is a glycoprotein hormone that belongs to the transforming growth factor beta (TGF-β) superfamily of growth and differentiation factors secreted by immature Sertoli cells (after castration, AMH is no longer detected in serum) and by granulosa cells of growing ovarian follicles. In males, it induces the regression of fetal Müllerian ducts and represses androgen synthesis through receptors..."

New page

'''Anti-Müllerian hormone'''(AMH), also known as Müllerian inhibiting substance, is a glycoprotein hormone that belongs to the transforming growth factor beta (TGF-β) superfamily of growth and differentiation factors secreted by immature Sertoli cells (after castration, AMH is no longer detected in serum) and by granulosa cells of growing ovarian follicles. In males, it induces the regression of fetal Müllerian ducts and represses androgen synthesis through receptors located on the Leydig cell membrane. In female, AMH inhibits primary follicle recruitment and sensitivity to [[Follicle-stimulating hormone (FSH)]].
AMH is synthesized as a homodimeric precursor consisting of two identical polypeptide chains, with a large N-terminal pro-region of 110-kDa and a small C-terminal mature domain of 25-kDa. AMH is subjected to post-translational proteolytic processing; the resulting N-terminal and C-terminal dimers remain associated in a non-covalent complex that is biologically active.<ref>Rajpert-De Meyts, E., Jørgensen, N., Græm, N., Müller, J., Cate, R. L., & Skakkebæk, N. E. (1999). Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. The Journal of Clinical Endocrinology & Metabolism, 84(10), 3836-3844. PMID: 10523039 DOI: 10.1210/jcem.84.10.6047</ref>

<ref>Durlinger, A., Visser, J., & Themmen, A. (2002). Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction. PMID: 12416998 DOI: 10.1530/rep.0.1240601</ref>
The measurement of circulating anti-Müllerian hormone (AMH) has been applied to a wide array of clinical applications, mainly based on its ability to reflect the number of antral and pre-antral follicles present in the ovaries. AMH has been suggested to predict the ovarian response to hyperstimulation of the ovaries for IVF and the timing of menopause, and to indicate iatrogenic damage to the ovarian follicle reserve. It has also been proposed as a surrogate for antral follicle count (AFC) in the diagnosis of polycystic ovary syndrome (PCOS).

<ref>Nelson, S. M., Davis, S. R., Kalantaridou, S., Lumsden, M. A., Panay, N., & Anderson, R. A. (2023). Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. Human Reproduction Update.</ref>
<ref>Holt, R., Yahyavi, S. K., Kooij, I., Andreassen, C. H., Andersson, A. M., Juul, A., ... & Blomberg Jensen, M. (2023). Low serum anti-Müllerian hormone is associated with semen quality in infertile men and not influenced by vitamin D supplementation. BMC medicine, 21(1), 79.</ref>
<ref>Sivanandy, M. S., & Ha, S. K. (2023). The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome. Diagnostics, 13(5), 907.</ref>

(AMH) is an ideal biomarker for the assessment of ovarian reserve. However, the ovarian reserve of premature ovarian insufficiency (POI) patients declines over time even under hormone therapy-treatment.<ref>Kuang, X., Wei, L., Huang, Y., Ji, M., Tang, Y., Wei, B., ... & Xu, H. (2023). Development of a digital anti-Müllerian hormone immunoassay: ultrasensitive, accurate and practical strategy for reduced ovarian reserve monitoring and assessment. Talanta, 253, 123970. PMID: 36206626 DOI: 10.1016/j.talanta.2022.123970</ref>